Reviva Pharmaceutcls Hldgs Inc Stock Price, News & Analysis

Reviva Pharmaceuticals (NASDAQ: RVPH) announced positive one-year data from its Phase 3 RECOVER open-label extension study of brilaroxazine for schizophrenia treatment. The study demonstrated sustained broad-spectrum efficacy across all symptom domains with a 35% discontinuation rate. The drug showed significant improvements in PANSS scores, with total score improvements of -10.7 at 6 months and -18.1 at 12 months. Safety data revealed only 8.5% of participants reported treatment-emergent adverse events, mostly mild (6.5%) or moderate (2.0%). Notable findings include minimal weight gain (1.52 kg), no drug-related serious adverse events, and improvements in multiple neuroinflammatory markers. The study's success supports brilaroxazine's potential as a novel treatment for schizophrenia, particularly addressing persistent negative symptoms and poor functional outcomes.

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for CNS, inflammatory and cardiometabolic diseases, has announced its participation in two upcoming investor conferences in May 2025.

CEO Laxminarayan Bhat will attend the Benchmark Healthcare House Call Virtual Investor Conference for a fireside chat and 1x1 meetings on May 29 at 11:15 a.m. ET, and the Lytham Partners Spring 2025 Investor Conference for a company presentation and 1x1 meetings on the same day at 2:00 p.m. ET. Both events will be held virtually.

Reviva Pharmaceuticals (NASDAQ: RVPH) reported Q1 2025 financial results and provided updates on its lead drug candidate brilaroxazine. The company completed its long-term open-label extension (OLE) trial with 446 participants, including 156 patients completing one year and 301 completing six months of treatment. The full dataset, including clinical response, safety, and biomarker data, is expected in Q2 2025. Reviva plans to initiate the Phase 3 RECOVER-2 trial in mid-2025 and targets an NDA submission in Q4 2026. Financially, Reviva reported a net loss of $6.4 million ($0.13 per share) for Q1 2025, compared to $7.4 million in Q1 2024. Cash position stood at $5.3 million as of March 31, 2025, down from $13.5 million at the end of 2024.

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming A.G.P. Healthcare Company Showcase. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat during the virtual event scheduled for May 21, 2025, at 2:00 p.m. EST.

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update through a fireside chat format.

The presentation is scheduled for Thursday, May 8, 2025, at 10:30 a.m. ET. Reviva focuses on developing therapies for:

• Central nervous system (CNS) diseases
• Inflammatory conditions
• Cardiometabolic diseases

The company aims to address unmet medical needs in these therapeutic areas. A webcast link has been provided for interested parties to access the presentation.

Reviva Pharmaceuticals (NASDAQ: RVPH) has announced an upcoming late-breaking poster presentation at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting. The presentation will focus on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia treatment.

The presentation, scheduled for May 28, 2025, from 11:15 a.m. to 1 p.m. MT at the Fairmont Scottsdale Princess in Arizona, will be delivered by Dr. Laxminarayan Bhat, the company's Founder, President, and CEO. The poster will detail brilaroxazine's effects on efficacy, safety, adherence, and biomarkers in patients with stable schizophrenia during the Phase 3 RECOVER trial extension.

Reviva, a late-stage pharmaceutical company, is developing therapies targeting unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases.

Reviva Pharmaceuticals (NASDAQ: RVPH) reported its 2024 financial results and key developments for brilaroxazine, its late-stage schizophrenia treatment. The preliminary topline data from the open-label extension (OLE) trial showed sustained efficacy over one year with dose-dependent improvements in PANSS scores ranging from -15.2 to -20.8 points across different dosages.

The drug demonstrated favorable safety with no single side effect exceeding 5% and a low treatment-related adverse event rate of 15.2%. The company reported a net loss of $29.9 million ($0.90 per share) for 2024, compared to $39.3 million in 2023. Cash position stood at $13.5 million as of December 31, 2024.

Key upcoming milestones include full OLE trial data analysis in Q2 2025, initiation of Phase 3 RECOVER-2 trial in mid-2025, and targeted NDA submission in Q4 2026. The company completed an $18 million public offering in December 2024.

Reviva Pharmaceuticals (NASDAQ: RVPH) has announced it will present topline data from the long-term open label extension portion of its Phase 3 RECOVER study for brilaroxazine in schizophrenia treatment at the 2025 SIRS Congress in Chicago.

The presentation, titled 'Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants,' will be delivered by Dr. Laxminarayan Bhat, Founder & CEO of Reviva Pharmaceuticals, on Sunday, March 30th from 10:30 AM to 12:00 PM CST.

The company, which focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, will showcase these results at the Schizophrenia International Research Society (SIRS) Congress, taking place March 29 to April 2, 2025.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.

The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update presentation at the virtual conference on Wednesday, February 12, 2025, at 2:40 p.m. ET. The event, scheduled for February 11-12, 2025, will be held entirely virtually, with a webcast link available for interested participants.